AU3236793A - Recombinant and chimeric antibodies to c-erbB-2 - Google Patents
Recombinant and chimeric antibodies to c-erbB-2Info
- Publication number
- AU3236793A AU3236793A AU32367/93A AU3236793A AU3236793A AU 3236793 A AU3236793 A AU 3236793A AU 32367/93 A AU32367/93 A AU 32367/93A AU 3236793 A AU3236793 A AU 3236793A AU 3236793 A AU3236793 A AU 3236793A
- Authority
- AU
- Australia
- Prior art keywords
- erbb
- recombinant
- chimeric antibodies
- chimeric
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80846291A | 1991-12-12 | 1991-12-12 | |
| US808462 | 1991-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3236793A true AU3236793A (en) | 1993-07-19 |
Family
ID=25198826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU32367/93A Abandoned AU3236793A (en) | 1991-12-12 | 1992-12-04 | Recombinant and chimeric antibodies to c-erbB-2 |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3236793A (en) |
| WO (1) | WO1993012220A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006217A1 (en) * | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| AU5098193A (en) * | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
| US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| SI1210115T1 (en) | 1999-08-27 | 2009-12-31 | Genentech Inc | DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| EP1282443B1 (en) | 2000-05-19 | 2009-09-02 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| EP2377555A3 (en) | 2004-11-18 | 2011-11-23 | Imclone LLC | Antibodies against vascular endothelial growth factor receptor-1 |
| UA94899C2 (en) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Fixed dosing of her antibodies |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| EP2132573B1 (en) | 2007-03-02 | 2014-04-23 | Genentech, Inc. | Predicting response to a her dimerisation inhbitor based on low her3 expression |
| DK2171090T3 (en) | 2007-06-08 | 2013-06-10 | Genentech Inc | Gene expression markers for tumor resistance to HER2 inhibitor therapy |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (en) | 2008-06-16 | 2010-06-22 | Genentech Inc | metastatic breast cancer treatment |
| ES2572728T3 (en) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Bispecific anti-HER antibodies |
| CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| CN102892779B (en) | 2010-02-18 | 2016-12-21 | 基因泰克公司 | Neuregulin antagonist and the purposes in treatment cancer thereof |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| JP5766296B2 (en) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components |
| MX2014001766A (en) | 2011-08-17 | 2014-05-01 | Genentech Inc | Neuregulin antibodies and uses thereof. |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| CN106987620A (en) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | Erbb3 mutation in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| JP2015514710A (en) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Diagnosis and treatment of HER3 inhibitors |
| WO2014083178A1 (en) | 2012-11-30 | 2014-06-05 | F. Hoffmann-La Roche Ag | Identification of patients in need of pd-l1 inhibitor cotherapy |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1992
- 1992-12-04 AU AU32367/93A patent/AU3236793A/en not_active Abandoned
- 1992-12-04 WO PCT/US1992/010437 patent/WO1993012220A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993012220A1 (en) | 1993-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3236793A (en) | Recombinant and chimeric antibodies to c-erbB-2 | |
| AU4025193A (en) | Humanized C-erbB-2 specific antibodies | |
| AU625613B2 (en) | Novel chimeric antibodies | |
| AU645187B2 (en) | Freeze-dried preparation containing monoclonal antibody | |
| AU5283893A (en) | Recombinant humanized anti-cytomegalovirus antibodies | |
| GR3033095T3 (en) | Anti-gp39 antibodies and uses therefor | |
| SG48420A1 (en) | Humanized antibodies and uses thereof | |
| AU5283793A (en) | Recombinant specific binding protein | |
| GB8800077D0 (en) | Novel chimeric antibodies | |
| AU4382193A (en) | BPI-immunoglobulin fusion proteins | |
| AU3342689A (en) | Luminescent chimeric proteins | |
| AU4618193A (en) | Humanized antibodies | |
| IL100764A0 (en) | Monoclonal antibodies to elam-1 and their uses | |
| GB9415380D0 (en) | Recombinant antibodies specific for tnf- | |
| AU635996B2 (en) | Recombinant human anti-cd18 antibodies | |
| GB9412166D0 (en) | Retargetting antibodies | |
| AU3665293A (en) | Chimeric toxins binding to the GnRH receptor | |
| AU4271793A (en) | Novel polypeptide | |
| AU1025692A (en) | Novel chimeric antiidiotypic monoclonal antibodies | |
| AU7796291A (en) | High affinity antibodies to small peptides | |
| NZ242056A (en) | Cd4-like chimeric peptides | |
| AU4889393A (en) | Human monoclonal anti-peptide antibody and DNA encoding thereof | |
| AU6059194A (en) | Monoclonal antibodies to bovine cytokines | |
| GB9220808D0 (en) | Antibody genes | |
| EP0491351A3 (en) | Chimeric antibodies and their use |